Pylclari 1 000 MBq/mL solution for injection

DRUG3 trials

Sponsors

Bayer Consumer Care AG, Bayer AG, Curium Pet France, Turku University Hospital

Conditions

Biochemically recurrent prostate cancerProstate cancermetastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2

99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging, PROSTAMIP

RecruitingCTIS2024-516083-28-00

Turku University HospitalProstate cancer

Start: 2022-06-01Target: 320Updated: 2024-12-20

Phase 3

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingCTIS2022-501493-19-00

Curium Pet Francemetastatic Castration-Resistant Prostate Cancer (mCRPC)

Start: 2023-02-20Target: 150Updated: 2025-10-28

(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer

Active, not recruitingCTIS2022-501343-33-00

Bayer Consumer Care AG, Bayer AGBiochemically recurrent prostate cancer

Start: 2023-10-18Target: 562Updated: 2026-01-21